Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859142 · ClinicalTrials.gov registry record · Phase 4
Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
NCT02859142 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 122 participants.
The verdict
NCT02859142, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if the combination of a study drug and patch is more effective in helping heavy drinkers stop smoking than just the patch alone The study drug, varenicline, has been approved by the Food and Drug Administration (FDA) to help people stop smoking, but it is not known if the addition of varenicline to standard smoking cessation treatment with nicotine patches will help people stop smoking who are regular, frequent drinkers. This study is being done because cigarette smoking is the number one preventable cause of death and disease in the United States.
Interventions
- DRUG Placebo
- DRUG Chantix
- BEHAVIORAL Behavioral Counseling Sessions
- DRUG NicodermCQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859142
The ClinicalTrials.gov registry entry for NCT02859142 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02859142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859142 about?
NCT02859142 is a clinical study titled "Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation". The purpose of this study is to learn if the combination of a study drug and patch is more effective in helping heavy drinkers stop smoking than just the patch alone The study drug, varenicline, has been approved by the Food and Drug Administration (FDA) to help people stop smoking, but it is not kn...
What is the current status of trial NCT02859142?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2018-03-29. Estimated completion is 2020-10-15.
What interventions are being tested in trial NCT02859142?
The interventions under investigation include: Placebo (DRUG), Chantix (DRUG), Behavioral Counseling Sessions (BEHAVIORAL), NicodermCQ (DRUG).
Who is sponsoring clinical trial NCT02859142?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.